Navigation Links
EpiCept Reports Second Quarter 2013 Operating and Financial Results
Date:7/31/2013

ture.  In July 2013, EpiCept and MidCap executed a Second Amendment to the Loan and Security Agreement in which the parties agreed that interest payments will continue to be made monthly and one half of the cash escrow will be returned to EpiCept upon the favorable stockholder vote to approve the final conditions to the closing of the merger.  Any past defaults under the loan agreement have been waived and principal payments on the existing loan will begin September 1, 2013 if the agreement restructuring the loan has not been completed.

Product PipelineFollowing the completion of the merger, IPI's product portfolio will consist of the following products:

  • Bertilimumab - a first in class monoclonal antibody (mAb) that targets eotaxin-1, a small protein that attracts and activates several sub-classes of immune cells, which are white blood cells that play a role in the development of several inflammatory diseases, including Crohn's Disease, ulcerative colitis, severe asthma and bullous pemphigoid, a dermatological auto-immune orphan condition with high unmet medical need. Eotaxin-1 has been shown to correlate with the severity of those diseases, which allows for selection of patients based on eotaxin-1 levels, a major step toward treatment personalization. Immune is currently initiating a multi-national Phase II trial of bertilimumab for the treatment of ulcerative colitis, and plans to initiate in late 2013 a Phase II trial for the treatment of bullous pemphigoid.  Data from these trials is expected to report during 2014.
  • NanomAbs -  an antibody drug conjugate (ADC) platform designed to deliver cancer drugs specifically to tumor cells thereby improving efficacy and reducing off-target undesirable effects.  Immune intends to continue development of its own candidates as well as to enter into partnerships where it will incorporate the partner's chemotherapeutic drug into the NanomAbs and/or power the partner's an
    '/>"/>

  • SOURCE EpiCept Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    2. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    3. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    6. Pharmasset Reports Fiscal Year End 2011 Financial Results
    7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    8. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    9. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    10. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    11. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
    (Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
    (Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
    (Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
    Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
    ... two years of the Governor's Business Plan Contest , the ... edge of its respective industry. This year's field of 27 finalists ... by start ups like Mithridion, Inc., the 2005 winner, and ... , ,As is the custom, the winner will be announced on ...
    ... , Wis. - Ralph Kauten is taking direct aim ... just passed an early test. , ,Kauten, CEO of ... initial screening of its PreserveX Polymeric Micelles, a core product. ... that enter the body and is used to determine whether ...
    ... Madison, Wis. - As part of its $6 ... $400 million to extend coverage to customers in Wisconsin and ... continues from 2005, when Cingular invested more $300 million in ... between Illinois and Wisconsin. , ,Since the start of 2006, ...
    Cached Biology Technology:Business plan finalists offer peek into entrepreneurial future 2Business plan finalists offer peek into entrepreneurial future 3Business plan finalists offer peek into entrepreneurial future 4QBI's PreserveX product passes initial test 2QBI's PreserveX product passes initial test 3
    (Date:12/22/2014)... DUBLIN , Dec. 22, 2014 /PRNewswire/ ... ) has announced the addition of the ... report to their offering. ... This insight provides an overview of the ... Watermarking aims to control and monitor piracy ...
    (Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the ... a study that pinpoints fine-scale differences in genetic ancestry ... . Since immigrants first arrived more ... States has served as a meeting place ... American history and the ongoing mixing of peoples with ...
    (Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to ... This accomplishment enables HITLAB to conduct regulated smart ... highest principles for patient safety and research quality. ... healthcare access, quality, and delivery with innovative technology," ...
    Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
    ... Nearctic deposited in the United States National Museum of ... Collection of Insects, researchers have found 16 new species ... seven new species. The new species are described ... Species, and a Key of the Charipinae (Hymenoptera: Cynipoidea: ...
    ... nucleus. In this state it synthesises proteins and, even though ... fact its structure is governed by precise rules that are ... studied DNA by observing it experimentally with a variety of ... silico, that is to say, the study of DNA by ...
    ... century writer Adam Smith provided a workable metaphor for the ... of Nations," he argued that even as individuals strive, through ... contribute---as if under the influence of a "hidden hand"---to an ... physicist and alive in the 21st century he might be ...
    Cached Biology News:25 years of DNA on the computer 2The entropy of nations 2The entropy of nations 3The entropy of nations 4
    ... Large (Klenow) Fragment, Exonuclease Minus, is a ... 5´→3´ and the 3´→5´ exonuclease activities present ... (1,2). It is used for random primer ... (5). Klenow Fragment, Exonuclease Minus, will leave ...
    ... 8-iso PGE2 is one of several isoprostanes ... is a potent renal vasoconstrictor in the rat. ... with IC50 values of 0.5 and 5 µM, ... the rat at a concentration of 4 mg/kg/min, ...
    DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
    ... offers both high-speed and high-volume versatility ... rotor options, making it ideal for a ... Versatility , High-speed (up to 15,000 ... high-volume (4 x 250mL) swinging bucket rotors ...
    Biology Products: